financial results

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) reported on Tuesday its fourth quarter financial results for the three months ended Sept. 30., revealing an 11% year-over-year increase in net revenue to CA$161.6 million ($120.7 million). Moreover, the Canadian producer reported a 71% increase in...

C21 Investments Inc. (CSE:CXXI) (OTCQX:CXXIF) announced on Thursday its unaudited interim financial results for the third quarter ended Oct. 31, revealing a year-over-year and sequential decrease of 4.5% and 3.9%, respectively, in revenue to $6.9 million. However, the Vancouver-based vertically...

Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC Pink: BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30, 2023.  Numbers show: Cash of $524,454 (CA$709,681) by Sept. 30, vs. $636,483 by...

Canada-based all-mushroom producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements and management discussion and analysis for the three and six months ended Sept. 30, 2023. Numbers show: Cash and cash equivalents of $12.0 million (CA$16.4 million) by Sept. 30...

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) announced its third quarter financial results on Monday for the three months ended Sept. 30, 2023, revealing an 18% year-over-year drop in revenue. However, in Illinois the company’s wholesale revenue nearly tripled over the same period,...

Leef Brands, Inc. (CSE: LEEF) (OTC: LEEEF) announced its third-quarter results Tuesday for the three months ended Sept. 30, 2023, revealing a 19% year-over-year decrease in revenue to $5.7 million. For the nine months ended Sept. 30, 2023, revenue totaled $24.6 million, representing a year-...

AYR Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) reported its third quarter financial results on Thursday for the three months ended Sept. 30, 2023. “We continued to execute on our optimization initiatives during the quarter, as reflected by another strong period of year-over-year adjusted...

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023. Cash totaled $13.25 (CA$18.1) million by Sept. 30, vs. $13.17 million by August 14, $6.81 million by June 30, and $12.17 million by March 31, 2023....

Unrivaled Brands, Inc. (OTCQB: UNRV) reported its third quarter financial results Tuesday for the three months ended Sept. 30, 2023, revealing an 11.4% year-over-year drop in revenue to $8.6 million. The Santa Ana, California-based company said that 94% of revenue was driven by its four...

Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) reported its third quarter financial results on Tuesday for the three months ended Sept. 30, 2023, revealing a 5% year-over-year increase in revenue to CA$10 million ($7.26 million). The Canadian cannabis producer also touted a sixth...

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) released its financial and operating results on Wednesday for the third quarter ended Sept. 30, 2023, revealing a 9.4% year-over-year decrease in revenue to $190.5 million. In the first quarter of fiscal 2023, the company initiated the year-...

Acreage Holdings, Inc. (CSE: ACRG.A.U) (ACRG.B.U) (OTCQX: ACRDF) reported its financial results Tuesday for the third quarter ended Sept. 30, 2023, revealing consolidated revenue of $56.5 million, an 8% year-over-year and 2.8% quarter-over-quarter decrease. The New York-based...

The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its  financial results for Q3 2023 ended September 30, showing: Cash, cash equivalents and other financial assets and marketable securities totaled $228.7 million by Sept. 30, compared to $251.7 million by...

Ispire Technology Inc. (NASDAQ: ISPR) reported its first quarter financial results on Tuesday, revealing a 59.1% year-over-year increase in revenue to $42.9 million in the three months ended Sept. 30, 2023. Cannabis vaping products contributed $17.3 million to revenue during the fiscal first...

Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing: Cash and cash equivalents of $4.27...